Association of glucose transporter 1 polymorphisms with type 2 diabetes in the Tunisian population

2008 ◽  
Vol 24 (7) ◽  
pp. 544-548 ◽  
Author(s):  
K. Makni ◽  
F. Mnif ◽  
M. Boudawara ◽  
N. Hamza ◽  
N. Rekik ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Transporter ◽  
Tunisian Population ◽  
Glucose Transporter 1

scholarly journals Transient Silencing of a Type IV P-Type ATPase,Atp10c, Results in Decreased Glucose Uptake in C2C12 Myotubes

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
S. E. Hurst ◽  
S. C. Minkin ◽  
J. Biggerstaff ◽  
M. S. Dhar
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Uptake ◽  
Glucose Transporter ◽  
Mapk Pathway ◽  
Specific Inhibitor ◽  
C2c12 Myotubes ◽  
Glucose Transporter 1 ◽  
Transfected Cells

Atp10cis a strong candidate gene for diet-induced obesity and type 2 diabetes. To identify molecular and cellular targets of ATP10C,Atp10cexpression was alteredin vitroin C2C12 skeletal muscle myotubes by transient transfection with anAtp10c-specific siRNA. Glucose uptake assays revealed that insulin stimulation caused a significant 2.54-fold decrease in 2-deoxyglucose uptake in transfected cells coupled with a significant upregulation of native mitogen-activated protein kinases (MAPKs), p38, and p44/42. Additionally, glucose transporter-1 (GLUT1) was significantly upregulated; no changes in glucose transporter-4 (GLUT4) expression were observed. The involvement of MAPKs was confirmed using the specific inhibitor SB203580, which downregulated the expression of native and phosphorylated MAPK proteins in transfected cells without any changes in insulin-stimulated glucose uptake. Results indicate thatAtp10cregulates glucose metabolism, at least in part via the MAPK pathway, and, thus, plays a significant role in the development of insulin resistance and type 2 diabetes.

scholarly journals Changes in FGF21 Serum Concentrations and Liver mRNA Expression in an Experimental Model of Complete Lipodystrophy and Insulin-Resistant Diabetes

2014 ◽  
pp. 483-490 ◽  
Author(s):  
A. ŠPOLCOVÁ ◽  
M. HOLUBOVÁ ◽  
B. MIKULÁŠKOVÁ ◽  
V. NAGELOVÁ ◽  
A. ŠTOFKOVÁ ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Mrna Expression ◽  
Plasma Levels ◽  
Glucose Transporter ◽  
Liver Fat ◽  
Fibroblast Growth Factor 21 ◽  
Glucose Transporter 1 ◽  
Insulin Resistant

Patients with obesity and type 2 diabetes often display high levels of the anti-diabetic factor fibroblast growth factor-21 (FGF21), suggesting that the overproduction of FGF21 may result from increased adiposity in an attempt by white adipose tissue (WAT) to counteract insulin resistance. However, the production of FGF21 diabetes in the absence of WAT has not been examined. In this study, we investigated the effects of lipodystrophy in A-ZIP F-1 mice on FGF21 production in relation to diabetes. A-ZIP F-1 mice displayed high FGF21 plasma levels resulting from enhanced FGF21 mRNA expression in the liver. Concomitant enhancement of FGF21 receptor (FGFR1) and glucose transporter 1 (GLUT-1) mRNA expression was observed in the muscles of A-ZIP F-1 mice. Furthermore, the activation of hypothalamic NPY and AgRP mRNA expression positively correlated with plasma levels of FGF21 but not active ghrelin. Our study demonstrates that an increased FGF21 plasma level in lipodystrophic A-ZIP F-1 mice results mainly from up-regulated liver production but does not suffice to overcome the lipodystrophy-induced severe type 2-diabetes and insulin resistance in the liver linked to the augmented liver fat deposition.

scholarly journals Association of rs10830963 MTNR1B and rs841853 SLC2A1 Polymorphism with Obesity on Type 2 Diabetes Patients: An Overview of Melatonin Receptor and Transporter

2021 ◽  
Vol 13 (2) ◽  
pp. 155-62
Author(s):  
Yanuarita Tursinawati ◽  
Arum Kartikadewi ◽  
Ari Yuniastuti ◽  
R Susanti
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Glucose Transporter ◽  
Cross Sectional Study ◽  
Melatonin Receptor ◽  
Cross Sectional ◽  
Glucose Transporter 1 ◽  
Genotype Frequencies ◽  
Significant Difference

BACKGROUND: One of the hormones that plays a role in glucose metabolism of Type 2 Diabetes Mellitus (T2DM) is melatonin. Its genetic variation is believed to play a significant role in the pathophysiology of obese and non-obese T2DM. The role of MTNR1B (melatonin receptor coding gene) and SLC2A1 (Glucose transporter 1/GLUT 1 transporter coding gene) on the risk of obese and non-obese T2DM patients is controversial. This study aims to analyze the association between the rs10830963 MTNR1B and rs841853 SLC2A1 polymorphism to the risk of Javanese obese T2DM.METHODS: This was a cross-sectional study that involved 107 Javanese T2DM patients from primary heath care in Semarang. Furthermore, obese T2DM was defined by a body mass index (BMI) more than 25 kg/m2. The genetic variations examined were rs10830963 MTNR1B and rs841853 SLC2A1 polymorphism by PCR-RFLP methods. Blood biochemistry parameters were also examined. Allele and genotype frequencies of rs10830963 MTNR1B and rs841853 SLC2A1 polymorphisms were analyzed using the x2 test with p≤0.05 and 95% CI.RESULTS: There was a significant association between rs10830963 MTNR1B polymorphisms in obese and nonobese T2DM (p=0.044) and the CG genotype increased the risk of obese T2DM. Furthermore, the allele and genotype frequency of rs841853 SLC2A1 polymorphism in both group had no significant difference, with a p=0.756 and p=0.802, respectively. There was also no significant difference in the biochemical parameters' in both groups of the two genetic variants studied.CONCLUSION: The rs10830963 MTNR1B polymorphism is associated with the risk of obesity in Javanese T2DM patients but not for the rs841853 SLC2A1 polymorphism.KEYWORDS: polymorphism, MTNR1B, SLC2A1, obese, diabetes mellitus

Gene polymorphisms in patients with type 2 diabetes and diabetic nephropathy

2012 ◽  
Vol 7 (2) ◽  
pp. 210-218 ◽  
Author(s):  
Hana Demova ◽  
Jana Boleckova ◽  
Daniela Rose ◽  
Hannes Koeppel ◽  
Bohumir Prochazka ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Nephropathy ◽  
Angiotensin Converting Enzyme ◽  
Glucose Transporter ◽  
Diabetic Patients ◽  
Enos Gene ◽  
Converting Enzyme ◽  
Glucose Transporter 1 ◽  
Patients With Diabetes

AbstractA considerable variability in the incidence and prevalence of diabetic nephropathy (DN) coheres with an important contribution of multigenetic predisposition in the development of DN. Some genes, which probably participate in the pathogenesis of diabetic nephropathy, also play a role in the regulation of blood pressure, familial hyperlipidemia, familial hypertension and other diseases of the cardiovascular system. We have examined the association of diabetic nephropathy, nephropathy of non-diabetic origin, hypertension and of type 2 diabetes itself with several genetic polymorphisms (the insertion/deletion polymorphism in the gene for angiotensin-converting enzyme, the G/T polymorphism in the glucose transporter 1 gene, the G/T (894) polymorphism and the T/C (−786) polymorphism in the eNOS gene in three groups of patients with diabetes mellitus: 1) patients without diabetic nephropathy (DM); 2) patients with DN; 3) patients with nephropathy of non-diabetic origin (NDRD). Angiotensin-converting enzyme is an important factor in a development of arterial hypertension, but in our groups of Central European diabetic patients the I/D polymorphism was not associated with diabetic nephropathy. Furthermore, we have confirmed that the T/C (T786C) polymorphism in the eNOS gene is associated with metabolic syndrome including type 2 diabetes.

Efficacy and cardiovascular safety of Thiazolidinediones

2020 ◽  
Vol 15 ◽  
Author(s):  
Raveendran Arkiath Veettil ◽  
Cornelius James Fernandez ◽  
Koshy Jacob
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Glucose Transporter ◽  
Cell Function ◽  
Cardiovascular Safety ◽  
Cardiovascular Outcome Trials ◽  
Glucose Transporter 2 ◽  
Insulin Sensitizers

: Type 2 diabetes mellitus (T2DM) is characterized by a progressive beta cell dysfunction in the setting of peripheral insulin resistance. Insulin resistance in subjects with type 2 diabetes and metabolic syndrome is primarily caused by an ectopic fat accumulation in liver and skeletal muscle. Insulin sensitizers are particularly important in the management of T2DM. Though, thiazolidinediones (TZDs) are principally insulin sensitizers, they possess an ability to preserve pancreatic β-cell function and thereby exhibit durable glycemic control. Cardiovascular outcome trials (CVOTs) have shown that Glucagon-like-peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose transporter-2 inhibitors (SGLT2i) have proven cardiovascular safety. In this era of CVOTs, drugs with proven cardiovascular (CV) safety are often preferred in patients with preexisting cardiovascular disease or at risk of cardiovascular disease. In this review, we will describe the three available drugs belonging to the TZD family, with special emphasis on their efficacy and CV safety.

scholarly journals Validation of DIABSCORE in screening for Type 2 Diabetes and prediabetes in Tunisian population

PLoS ONE ◽  
2018 ◽  
Vol 13 (8) ◽  
pp. e0200718
Author(s):  
Fadoua Gannar ◽  
María del Cristo Rodriguez-Pérez ◽  
Santiago Domínguez Coello ◽  
Khedija Haouet ◽  
Buenaventura Brito Díaz ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Tunisian Population
Sign in / Sign up

Export Citation Format

Share Document